Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia — The PUSH-PATH3 Study
| Autor: | Li Tian, Kunshen Liu, Gang Liu, Guo-Ping Ma, Yuzhi Zhen, Lishuang Ji, Hong Meng, Le Wang, Chao Liu, Mingqi Zheng, Lizhuo Li, Qingzhen Zhao, Linan Duan, Jianlong Zhai |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Immunology Urology Renal function Hyperuricemia Gout Suppressants chemistry.chemical_compound Rheumatology Prednisone Internal medicine medicine Humans Immunology and Allergy Urine output Aged Heart Failure Creatinine business.industry Serum uric acid Middle Aged medicine.disease Uric Acid Treatment Outcome Endocrinology chemistry Heart failure Uric acid Female business medicine.drug |
| Zdroj: | The Journal of Rheumatology. 42:866-869 |
| ISSN: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.141037 |
| Popis: | Objective.To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia.Methods.Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl).Results.Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, improvement in renal function, and improvement in clinical status.Conclusion.Prednisone can be used safely in symptomatic HF patients with hyperuricemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|